Pharmaceutical manufacturer Eli Lilly recently rolled out a new platform intended to boost employer coverage of GLP-1 medications for obesity.
Lilly will offer Zepbound, an injectable GLP-1 medication, at a price of $449 per month for all doses through the platform, called Lilly Connect. That’s the same price for higher doses of Zepbound available to patients without insurance coverage through the direct-to-consumer market, including on Trum
pRx.The model is one of several that allow employers to bypass
https://www.hr-brew.com/stories/2026/03/12/eli-lilly-direct-to-employer-coverage?utm_source=&utm_medium=syndication&utm_campaign=feed